LinkedIn post Isologic goes electric

🔌Isologic Goes Electric!

We are excited to announce the expansion of our electric fleet with the addition of the Mercedes-Benz eCitan. This compact and sustainable vehicle boasts a range of approximately 280km and can be rapidly charged from 20% to 80% ursing fast-charging stations. 

Our commitment to electric mobility is driven by our collaboration with Radboud Translational Medicine B.V., where we transport medical isotopes daily to healthcare facilities both domestically and internationally. Furthermore, many of our clients are increasingly seeking sustainable logistics solutions. With the implementation of zero-emission zones in cities such as Nijmegen, and the expectation that more cities will follow this example, this is a significant step forward.

At Isologic, delivery reliability is paramount: it is crucial that hospitals receive the necessary medical sources on time for patient treatment. The Mercedes-Benz eCitan supports us in this mission with its dependable performance and swift charging capabilities.

A notable feature of this eCitan is its specialized software that optimizes temperature settings for efficient charging. We will now rigorously test the performance and reliability of this electric van, as we previously did with an electric FIAT Doblo. Interested in the results? Please contact us: https://lnkd.in/et8ny4EK

#Isologic hashtag#ElectricDriving hashtag#Sustainability hashtag#Logistics hashtag#Healthcare hashtag#ZeroEmission

LinkedIn post Isologic goes electric

Other news

RTM added as distributor NeuraCeq®

RTM added as distributor NeuraCeq®

Exciting news! Life Molecular Imaging’s NeuraCeq® 300 MBq/ml solution for injection (florbetaben 18F...

Read more

Cooperation RTM-Alliance Medical

Cooperation RTM-Alliance Medical

It is with great pleasure that we announce our cooperation with Alliance Medical Group (AMG) regardi...

Read more

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

Read more

Upcoming event

Upcoming event

From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress o...

Read more

Interested in a collaboration?

Contact us to discuss the possibilities.